Table 1.
Baseline characteristics.
| Study Population (n = 191) | High AZGP1 (n = 97) |
Low AZGP1 (n = 94) |
p-Value | |
|---|---|---|---|---|
| Age at treatment start, years, median (range) | 70.0 (52.4–89.7) | 70.6 (52.4–89.7) | 69.5 (52.5–89.1) | 0.3 |
| PSA at treatment start, µg/L, median (IQR) | 62.0 (30.0–202.5) | 68.0 (30.0–187.0) | 57.5 (30.0–228.0) | 0.9 |
| Clinical tumor category, n (%) | 0.05 | |||
| ≤cT2 | 32 (16.8) | 22 (22.7) | 10 (10.6) | |
| cT3a | 61 (31.9) | 34 (35.1) | 27 (28.7) | |
| cT3b | 59 (30.9) | 25 (25.8) | 34 (36.2) | |
| cT4 | 39 (20.4) | 16 (16.5) | 23 (24.5) | |
| Diagnostic Gleason score, n (%) | 0.002 | |||
| ≤7 | 38 (19.9) | 28 (28.9) | 10 (10.6) | |
| 8 | 59 (30.9) | 31 (32.0) | 28 (29.8) | |
| 9–10 | 94 (49.2) | 38 (39.2) | 56 (59.6) | |
| Lymph node stage, n (%) | 0.4 | |||
| N0 | 1 (0.5) | 0 (0.0) | 1 (1.1) | |
| N1 | 54 (28.3) | 25 (25.8) | 29 (30.9) | |
| Nx | 136 (71.2) | 72 (74.2) | 64 (68.1) | |
| Metastasis at diagnosis, n (%) | 0.1 | |||
| M0 | 70 (36.6) | 38 (39.2) | 32 (34.0) | |
| M1 | 114 (59.7) | 53 (54.6) | 61 (64.9) | |
| Mx | 7 (3.7) | 6 (6.2) | 1 (1.1) | |
| Stage of disease *, n (%) | 0.3 | |||
| Locally advanced | 40 (20.9) | 22 (22.7) | 18 (19.1) | |
| Lymph node metastases only | 37 (19.4) | 22 (22.7) | 15 (16.0) | |
| Distant metastases | 114 (59.7) | 53 (54.6) | 61 (64.9) | |
| Primary ADT treatment, n (%) | 0.2 | |||
| LHRH treatment | 176 (92.1) | 89 (91.8) | 87 (92.6) | |
| Maximal androgen blockade | 8 (4.2) | 6 (6.2) | 2 (2.1) | |
| Orchiectomy | 7 (3.7) | 2 (2.1) | 5 (5.3) |
p-value: Wilcoxon rank-sum test for continuous variables and ײ test for categorical variables. Abbreviations: IQR: Interquartile range; LHRH: Luteinizing hormone-releasing hormone; TRUS: Transrectal ultrasound; PSA: Prostate-specific antigen. * Locally advanced: N0/Nx and M0/Mx; Lymph node metastases only: N1 and M0/Mx; Distant metastases: M1 and N0/Nx/N1.